The Generic Drugs Market Report 2024-2034: This report will prove invaluable to leading firms striving for new revenue pockets if they wish to better understand the industry and its underlying dynamics. It will be useful for companies that would like to expand into different industries or to expand their existing operations in a new region.
Rising Geriatric Population and Cost Affordability of Generic Drugs Projected to Boost Industry Growth
The generic drugs market is expected to be significantly driven by key factors such as the rising geriatric population and the cost affordability and effectiveness of generic medications. As the global demographic structure shifts towards an aging population, the prevalence of chronic diseases increases, necessitating long-term treatments. Generic drugs, known for their therapeutic equivalence to brand-name counterparts and cost-effectiveness, emerge as crucial solutions to meet the healthcare needs of the elderly. The affordability of generic drugs aligns with the economic constraints often faced by seniors, fostering widespread adoption. Governments and healthcare systems, recognizing the financial advantages and accessibility benefits of generic drugs, are likely to support policies and initiatives that further propel market growth. The combination of a growing elderly population seeking affordable treatments and the proven effectiveness of generic drugs positions this market to play a pivotal role in addressing healthcare challenges and ensuring broader access to essential medications.
Adverse Effects Associated with Drugs Likely to Challenge Market Growth
Adverse effects associated with drugs are anticipated to pose a substantial challenge for the generic drugs market. While generic medications aim to replicate the therapeutic effects of their brand-name counterparts, the one-size-fits-all approach may not adequately address individual variations in patient response. This lack of individualized formulations raises concerns about potential adverse reactions, as patients may experience side effects or inadequate therapeutic responses. Variability in bioavailability among generic drugs further complicates the scenario, potentially leading to variations in drug concentration levels and subsequent adverse effects. Moreover, differences in inactive ingredients between generic and brand-name drugs may impact tolerability, especially for individuals with allergies or sensitivities, creating a need for standardized formulations. The limited post-market surveillance for generic drugs compared to brand-name counterparts raises challenges in timely identification and management of adverse effects, impacting consumer confidence. Addressing these adverse effects associated with generic drugs requires enhanced regulatory measures, rigorous quality control, and a focus on individualized medicine to ensure the sustained growth and success of the generic drugs market.
What Questions Should You Ask before Buying a Market Research Report?
- How is the generic drugs market evolving?
- What is driving and restraining the generic drugs market?
- How will each generic drugs submarket segment grow over the forecast period and how much revenue will these submarkets account for in 2034?
- How will the market shares for each generic drugs submarket develop from 2024 to 2034?
- What will be the main driver for the overall market from 2024 to 2034?
- Will leading generic drugs markets broadly follow the macroeconomic dynamics, or will individual national markets outperform others?
- How will the market shares of the national markets change by 2034 and which geographical region will lead the market in 2034?
- Who are the leading players and what are their prospects over the forecast period?
- How will the industry evolve during the period between 2024 and 2034? What are the implications of generic drugs projects taking place now and over the next 10 years?
- Is there a greater need for product commercialisation to further scale the generic drugs market?
- Where is the generic drugs market heading and how can you ensure you are at the forefront of the market?
- What are the best investment options for new product and service lines?
- What are the key prospects for moving companies into a new growth path and C-suite?
You need to discover how this will impact the Generic Drugs Market today, and over the next 10 years:
- Our 357-page report provides 133 tables, 223 charts/graphs exclusively to you.
- The report highlights key lucrative areas in the industry so you can target them – NOW.
- It contains in-depth analysis of global, regional and national sales and growth.
- It highlights for you the key successful trends, changes and revenue projections made by your competitors.
This report tells you TODAY how the Generic Drugs Market will develop in the next 10 years, and in line with the variations in COVID-19 economic recession and bounce. This market is more critical now than at any point over the last 10 years.
Forecasts to 2034 and other analyses reveal commercial prospects
- In addition to revenue forecasting to 2034, our new study provides you with recent results, growth rates, and market shares.
- You will find original analyses, with business outlooks and developments.
- Discover qualitative analyses (including market dynamics, drivers, opportunities, restraints and challenges), cost structure, impact of rising generic drugs prices and recent developments.
This report includes data analysis and invaluable insight into how COVID-19 will affect the industry and your company. Four COVID-19 recovery patterns and their impact, namely, “V”, “L”, “W” and “U” are discussed in this report.
Segments Covered in the Report
Type
- Simple Generics
- Specialty Generics
- Biosimilars
Route of Administration
- Oral
- Parenteral
- Topical
- Others
Indication
- Central Nervous System (CNS)
- Oncology
- Infectious Diseases
- Cardiovascular Diseases
- Gastrointestinal Diseases
- Musculoskeletal Diseases
- Others
Drug Class
- Antibiotics
- Antihistamines
- Analgesics
- Antihypertensive
- Antidiabetic
- Antipyretic
- Others
Prescription Type
- Prescription Generics
- Over-the-Counter (OTC) Generics
Distribution Channel
- Retail Pharmacies
- Hospital Pharmacies
- Online Pharmacies
- Others
In addition to the revenue predictions for the overall world market and segments, you will also find revenue forecasts for five regional and 20 leading national markets:
North America
Europe
- Germany
- UK
- France
- Italy
- Spain
- Rest of Europe
Asia Pacific
- China
- Japan
- India
- Australia
- South Korea
- Rest of Asia Pacific
Latin America
- Brazil
- Argentina
- Rest of Latin America
MEA
- GCC Countries
- South Africa
- Rest of MEA
Need industry data? Please contact us today.
The report also includes profiles and for some of the leading companies in the Generic Drugs Market, 2024 to 2034, with a focus on this segment of these companies’ operations.
Leading companies and the potential for market growth
- Alkem Laboratories Ltd.
- Amneal Pharmaceuticals LLC
- Aurobindo Pharma
- Biocon
- Cipla Inc.
- Dr. Reddy’s Laboratories Ltd.
- Endo International plc
- Lupin
- Novartis AG
- Sun Pharmaceuticals Industries Ltd.
- Teva Pharmaceutical Industries Ltd.
- Torrent Pharmaceuticals Ltd.
- Viatris Inc.
Overall world revenue for Generic Drugs Market, 2024 to 2034 in terms of value the market will surpass US$450.0 billion in 2024, our work calculates. We predict strong revenue growth through to 2034. Our work identifies which organizations hold the greatest potential. Discover their capabilities, progress, and commercial prospects, helping you stay ahead.
How will the Generic Drugs Market, 2024 to 2034 report help you?
In summary, our 350+ page report provides you with the following knowledge:
- Revenue forecasts to 2034 for Generic Drugs Market, 2024 to 2034, with forecasts for type, prescription type, indication, drug class, route of administration, distribution channel, each forecast at a global and regional level – discover the industry’s prospects, finding the most lucrative places for investments and revenues.
- Revenue forecasts to 2034 for five regional and 20 key national markets – See forecasts for the Generic Drugs Market, 2024 to 2034 market in North America, Europe, Asia-Pacific, Latin America and MEA. Also forecasted is the market in the US, Canada, Brazil, Germany, France, UK, Italy, China, India, Japan, and Australia among other prominent economies.
- Prospects for established firms and those seeking to enter the market – including company profiles for 13 of the major companies involved in the Generic Drugs Market, 2024 to 2034.
Find quantitative and qualitative analyses with independent predictions. Receive information that only our report contains, staying informed with invaluable business intelligence.
Information found nowhere else
With our new report, you are less likely to fall behind in knowledge or miss out on opportunities. See how our work could benefit your research, analyses, and decisions. Visiongain’s study is for everybody needing commercial analyses for the Generic Drugs Market, 2024 to 2034, market-leading companies. You will find data, trends and predictions.
To access the data contained in this document please email contactus@visiongain.com
Buy our report today Generic Drugs Market Report 2024-2034: Forecasts by Type (Simple Generics, Specialty Generics, Biosimilars), by Prescription Type (Prescription Generics, Over-the-Counter (OTC) Generics)), by Indication (Central Nervous System (CNS), Oncology, Infectious Diseases, Cardiovascular Diseases, Gastrointestinal Diseases, Musculoskeletal Diseases, Others), by Drug Class (Antibiotics, Antihistamines, Analgesics, Antihypertensive, Antidiabetic, Antipyretic, Others), by Route of Administration (Oral, Parenteral, Topical, and Others), by Distribution Channel (Retail Pharmacies, Hospital Pharmacies, Online Pharmacies, Others) AND Regional and Leading National Market Analysis PLUS Analysis of Leading Companies AND COVID-19 Impact and Recovery Pattern Analysis. Avoid missing out by staying informed – order our report now.
Visiongain is a trading partner with the US Federal Government
CCR Ref number: KD4R6
Do you have any custom requirements we can help you with? Any need for a specific country, geo region, market segment or specific company information? Contact us today, we can discuss your needs and see how we can help: contactus@visiongain.com
1 Report Overview
1.1 Objectives of the Study
1.2 Introduction to Generic Drugs Market
1.3 What This Report Delivers
1.4 Why You Should Read This Report
1.5 Key Questions Answered by This Analytical Report
1.6 Who is This Report for?
1.7 Methodology
1.7.1 Market Definitions
1.7.2 Market Evaluation & Forecasting Methodology
1.7.3 Data Validation
1.7.3.1 Primary Research
1.7.3.2 Secondary Research
1.8 Frequently Asked Questions (FAQs)
1.9 Associated Visiongain Reports
1.10 About Visiongain
2 Executive Summary
3 Market Overview
3.1 Key Findings
3.2 Market Dynamics
3.2.1 Market Driving Factors
3.2.1.1 Cost Affordability and Effectiveness of Generic Drugs
3.2.1.2 Strategic Partnerships among Generic Drugs Manufacturers
3.2.1.3 Rise in Geriatric Population
3.2.1.4 Rise in Chronic Disorders
3.2.1.5 Rising Government Initiative to Promote Generic Drugs
3.2.2 Market Restraining Factors
3.2.2.1 Stringent Government Regulations
3.2.2.2 Brand Loyalty
3.2.2.3 Intellectual Property Lawsuits and Patent Disputes
3.2.2.4 Adverse Effects Associated with the Drugs
3.2.3 Market Opportunities
3.2.3.1 Patent Expiration of Blockbuster Drugs in this Decade
3.2.3.2 Growth of Biologics and Biosimilars
3.3 COVID-19 Impact Analysis
3.4 Porter’s Five Forces Analysis
3.4.1 Bargaining Power of Suppliers
3.4.2 Bargaining Power of Buyers
3.4.3 Competitive Rivalry
3.4.4 Threat from Substitutes
3.4.5 Threat of New Entrants
3.5 PEST Analysis
3.5.1 Political
3.5.2 Economical
3.5.3 Social
3.5.4 Technological
4 Generic Drugs Market Analysis by Type
4.1 Key Findings
4.2 Type Segment: Market Attractiveness Index
4.3 Generic Drugs Market Size Estimation and Forecast by Type
4.4 Simple Generics
4.4.1 Market Size by Region, 2024-2034 (US$ Billion)
4.4.2 Market Share by Region, 2024 & 2034 (%)
4.5 Specialty Generics
4.5.1 Market Size by Region, 2024-2034 (US$ Billion)
4.5.2 Market Share by Region, 2024 & 2034 (%)
4.6 Biosimilars
4.6.1 Market Size by Region, 2024-2034 (US$ Billion)
4.6.2 Market Share by Region, 2024 & 2034 (%)
5 Generic Drugs Market Analysis by Prescription Type
5.1 Key Findings
5.2 Prescription Type Segment: Market Attractiveness Index
5.4 Generic Drugs Market Size Estimation and Forecast by Prescription Type
5.5 Prescription Generics
5.5.1 Market Size by Region, 2024-2034 (US$ Billion)
5.5.2 Market Share by Region, 2024 & 2034 (%)
5.6 Over-the-Counter (OTC) Generics
5.6.1 Market Size by Region, 2024-2034 (US$ Billion)
5.6.2 Market Share by Region, 2024 & 2034 (%)
6 Generic Drugs Market Analysis by Indication
6.1 Key Findings
6.2 Indication Segment: Market Attractiveness Index
6.4 Generic Drugs Market Size Estimation and Forecast by Indication
6.5 Central Nervous System (CNS)
6.5.1 Market Size by Region, 2024-2034 (US$ Billion)
6.5.2 Market Share by Region, 2024 & 2034 (%)
6.6 Oncology
6.6.1 Market Size by Region, 2024-2034 (US$ Billion)
6.6.2 Market Share by Region, 2024 & 2034 (%)
6.7 Infectious Diseases
6.7.1 Market Size by Region, 2024-2034 (US$ Billion)
6.7.2 Market Share by Region, 2024 & 2034 (%)
6.8 Cardiovascular Diseases
6.8.1 Market Size by Region, 2024-2034 (US$ Billion)
6.8.2 Market Share by Region, 2024 & 2034 (%)
6.9 Gastrointestinal Diseases
6.9.1 Market Size by Region, 2024-2034 (US$ Billion)
6.9.2 Market Share by Region, 2024 & 2034 (%)
6.10 Musculoskeletal Diseases
6.10.1 Market Size by Region, 2024-2034 (US$ Billion)
6.10.2 Market Share by Region, 2024 & 2034 (%)
6.11 Others
6.11.1 Market Size by Region, 2024-2034 (US$ Billion)
6.11.2 Market Share by Region, 2024 & 2034 (%)
7 Generic Drugs Market Analysis by Drug Class
7.1 Key Findings
7.2 Drug Class Segment: Market Attractiveness Index
7.4 Generic Drugs Market Size Estimation and Forecast by Drug Class
7.5 Antibiotics
7.5.1 Market Size by Region, 2024-2034 (US$ Billion)
7.5.2 Market Share by Region, 2024 & 2034 (%)
7.6 Antihistamines
7.6.1 Market Size by Region, 2024-2034 (US$ Billion)
7.6.2 Market Share by Region, 2024 & 2034 (%)
7.7 Analgesics
7.7.1 Market Size by Region, 2024-2034 (US$ Billion)
7.7.2 Market Share by Region, 2024 & 2034 (%)
7.8 Antihypertensive
7.8.1 Market Size by Region, 2024-2034 (US$ Billion)
7.8.2 Market Share by Region, 2024 & 2034 (%)
7.9 Antidiabetic
7.9.1 Market Size by Region, 2024-2034 (US$ Billion)
7.9.2 Market Share by Region, 2024 & 2034 (%)
7.10 Antipyretic
7.10.1 Market Size by Region, 2024-2034 (US$ Billion)
7.10.2 Market Share by Region, 2024 & 2034 (%)
7.11 Others
7.11.1 Market Size by Region, 2024-2034 (US$ Billion)
7.11.2 Market Share by Region, 2024 & 2034 (%)
8 Generic Drugs Market Analysis by Route of Administration
8.1 Key Findings
8.2 Route of Administration Segment: Market Attractiveness Index
8.4 Generic Drugs Market Size Estimation and Forecast by Route of Administration
8.5 Oral
8.5.1 Market Size by Region, 2024-2034 (US$ Billion)
8.5.2 Market Share by Region, 2024 & 2034 (%)
8.6 Parenteral
8.6.1 Market Size by Region, 2024-2034 (US$ Billion)
8.6.2 Market Share by Region, 2024 & 2034 (%)
8.7 Topical
8.7.1 Market Size by Region, 2024-2034 (US$ Billion)
8.7.2 Market Share by Region, 2024 & 2034 (%)
8.8 Others
8.8.1 Market Size by Region, 2024-2034 (US$ Billion)
8.8.2 Market Share by Region, 2024 & 2034 (%)
9 Generic Drugs Market Analysis by Distribution Channel
9.1 Key Findings
9.2 Distribution Channel Segment: Market Attractiveness Index
9.4 Generic Drugs Market Size Estimation and Forecast by Distribution Channel
9.5 Hospital Pharmacies
9.5.1 Market Size by Region, 2024-2034 (US$ Billion)
9.5.2 Market Share by Region, 2024 & 2034 (%)
9.6 Retail Pharmacies
9.6.1 Market Size by Region, 2024-2034 (US$ Billion)
9.6.2 Market Share by Region, 2024 & 2034 (%)
9.7 Online Pharmacies
9.7.1 Market Size by Region, 2024-2034 (US$ Billion)
9.7.2 Market Share by Region, 2024 & 2034 (%)
9.8 Others
9.8.1 Market Size by Region, 2024-2034 (US$ Billion)
9.8.2 Market Share by Region, 2024 & 2034 (%)
10 Generic Drugs Market Analysis by Region
10.1 Key Findings
10.3 Regional Market Size Estimation and Forecast
11 North America Generic Drugs Market Analysis
11.1 Key Findings
11.2 North America Generic Drugs Market Attractiveness Index
11.3 North America Generic Drugs Market by Country, 2024, 2029 & 2034 (US$ Billion)
11.4 North America Generic Drugs Market Size Estimation and Forecast by Country
11.5 North America Generic Drugs Market Size Estimation and Forecast by Type
11.6 North America Generic Drugs Market Size Estimation and Forecast by Route of Administration
11.7 North America Generic Drugs Market Size Estimation and Forecast by Indication
11.8 North America Generic Drugs Market Size Estimation and Forecast by Drug Class
11.9 North America Generic Drugs Market Size Estimation and Forecast by Prescription Type
11.10 North America Generic Drugs Market Size Estimation and Forecast by Distribution Channel
11.11 U.S. Generic Drugs Market Analysis
11.12 Canada Generic Drugs Market Analysis
12 Europe Generic Drugs Market Analysis
12.1 Key Findings
12.2 Europe Generic Drugs Market Attractiveness Index
12.3 Europe Generic Drugs Market by Country, 2024, 2029 & 2034 (US$ Billion)
12.4 Europe Generic Drugs Market Size Estimation and Forecast by Country
12.5 Europe Generic Drugs Market Size Estimation and Forecast by Type
12.6 Europe Generic Drugs Market Size Estimation and Forecast by Route of Administration
12.7 Europe Generic Drugs Market Size Estimation and Forecast by Indication
12.8 Europe Generic Drugs Market Size Estimation and Forecast by Drug Class
12.9 Europe Generic Drugs Market Size Estimation and Forecast by Prescription Type
12.10 Europe Generic Drugs Market Size Estimation and Forecast by Distribution Channel
12.11 Germany Generic Drugs Market Analysis
12.12 UK Generic Drugs Market Analysis
12.13 France Generic Drugs Market Analysis
12.14 Italy Generic Drugs Market Analysis
12.15 Spain Generic Drugs Market Analysis
12.16 Rest of Europe Generic Drugs Market Analysis
13 Asia Pacific Generic Drugs Market Analysis
13.1 Key Findings
13.2 Asia Pacific Generic Drugs Market Attractiveness Index
13.3 Asia Pacific Generic Drugs Market by Country, 2024, 2029 & 2034 (US$ Billion)
13.4 Asia Pacific Generic Drugs Market Size Estimation and Forecast by Country
13.5 Asia Pacific Generic Drugs Market Size Estimation and Forecast by Type
13.6 Asia Pacific Generic Drugs Market Size Estimation and Forecast by Route of Administration
13.7 Asia Pacific Generic Drugs Market Size Estimation and Forecast by Indication
13.8 Asia Pacific Generic Drugs Market Size Estimation and Forecast by Drug Class
13.9 Asia Pacific Generic Drugs Market Size Estimation and Forecast by Prescription Type
13.10 Asia Pacific Generic Drugs Market Size Estimation and Forecast by Distribution Channel
13.11 Japan Generic Drugs Market Analysis
13.12 China Generic Drugs Market Analysis
13.13 India Generic Drugs Market Analysis
13.14 Australia Generic Drugs Market Analysis
13.15 South Korea Generic Drugs Market Analysis
13.16 Rest of Asia Pacific Generic Drugs Market Analysis
14 Latin America Generic Drugs Market Analysis
14.1 Key Findings
14.2 Latin America Generic Drugs Market Attractiveness Index
14.3 Latin America Generic Drugs Market by Country, 2024, 2029 & 2034 (US$ Billion)
14.4 Latin America Generic Drugs Market Size Estimation and Forecast by Country
14.5 Latin America Generic Drugs Market Size Estimation and Forecast by Type
14.6 Latin America Generic Drugs Market Size Estimation and Forecast by Route of Administration
14.7 Latin America Generic Drugs Market Size Estimation and Forecast by Indication
14.8 Latin America Generic Drugs Market Size Estimation and Forecast by Drug Class
14.9 Latin America Generic Drugs Market Size Estimation and Forecast by Prescription Type
14.10 Latin America Generic Drugs Market Size Estimation and Forecast by Distribution Channel
14.11 Brazil Generic Drugs Market Analysis
14.12 Argentina Generic Drugs Market Analysis
14.13 Rest of Latin America Generic Drugs Market Analysis
15 MEA Generic Drugs Market Analysis
15.1 Key Findings
15.2 MEA Generic Drugs Market Attractiveness Index
15.3 MEA Generic Drugs Market by Country, 2024, 2029 & 2034 (US$ Billion)
15.4 MEA Generic Drugs Market Size Estimation and Forecast by Country
15.5 MEA Generic Drugs Market Size Estimation and Forecast by Type
15.6 MEA Generic Drugs Market Size Estimation and Forecast by Route of Administration
15.7 MEA Generic Drugs Market Size Estimation and Forecast by Indication
15.8 MEA Generic Drugs Market Size Estimation and Forecast by Drug Class
15.9 MEA Generic Drugs Market Size Estimation and Forecast by Prescription Type
15.10 MEA Generic Drugs Market Size Estimation and Forecast by Distribution Channel
15.11 GCC Generic Drugs Market Analysis
15.12 South Africa Generic Drugs Market Analysis
15.13 Rest of MEA Generic Drugs Market Analysis
16 Company Profiles
16.1 Competitive Landscape, 2023
16.2 Novartis AG
16.2.1 Company Snapshot
16.2.2 Company Overview
16.2.3 Financial Analysis
16.2.3.1 Net Revenue, 2018-2022
16.2.3.2 Regional Market Shares, 2022
16.2.3.3 R&D Expense, 2018-2022
16.2.5 Product Benchmarking
16.2.6 Strategic Outlook
16.3 Teva Pharmaceutical Industries Ltd.
16.3.1 Company Snapshot
16.3.2 Company Overview
16.3.3 Financial Analysis
16.3.3.1 Revenue, 2018-2022
16.3.3.2 Regional Market Shares, 2022
16.3.3.3 R&D Expense, 2018-2022
16.3.5 Product Benchmarking
16.3.6 Strategic Outlook
16.4 Viatris Inc.
16.4.1 Company Snapshot
16.4.2 Company Overview
16.4.3 Financial Analysis
16.4.3.1 Revenue, 2018-2022
16.4.3.2 Regional Market Shares, 2022
16.4.3.3 R&D Expense, 2018-2022
16.4.5 Product Benchmarking
16.4.6 Strategic Outlook
16.5 Lupin
16.5.1 Company Snapshot
16.5.2 Company Overview
16.5.3 Financial Analysis
16.5.3.1 Revenue, 2018-2022
16.5.3.2 R&D Expense, 2018-2022
16.5.5 Product Benchmarking
16.5.6 Strategic Outlook
16.6 Alkem Laboratories Ltd.
16.6.1 Company Snapshot
16.6.2 Company Overview
16.6.3 Financial Analysis
16.6.3.1 Net Revenue, 2018-2022
16.6.3.2 Regional Market Shares, 2022
16.6.3.3 R&D Expense, 2018-2022
16.6.4 Product Benchmarking
16.6.5 Strategic Outlook
16.7 Cipla Inc.
16.7.1 Company Snapshot
16.7.2 Company Overview
16.7.3 Financial Analysis
16.7.3.1 Revenue, 2018-2022
16.7.3.2 Regional Market Shares, 2022
16.7.3.3 R&D Expense, 2018-2022
16.7.5 Product Benchmarking
16.7.6 Strategic Outlook
16.8 Biocon
16.8.1 Company Snapshot
16.8.2 Company Overview
16.8.3 Financial Analysis
16.8.3.1 Revenue, 2018-2022
16.8.3.2 Segmental Market Shares, 2022
16.8.3.3 R&D Expense, 2018-2022
16.8.5 Product Benchmarking
16.8.6 Strategic Outlook
16.9 Aurobindo Pharma
16.9.1 Company Snapshot
16.9.2 Company Overview
16.9.3 Financial Analysis
16.9.3.1 Revenue, 2018-2022
16.9.4 Product Benchmarking
16.9.5 Strategic Outlook
16.10 Endo International plc
16.10.1 Company Snapshot
16.10.2 Company Overview
16.10.3 Financial Analysis
16.10.3.1 Revenue, 2018-2022
16.10.3.2 R&D Expense, 2018-2022
16.10.4 Product Benchmarking
16.10.5 Strategic Outlook
16.11 Torrent Pharmaceuticals Ltd.
16.11.1 Company Snapshot
16.11.2 Company Overview
16.11.3 Financial Analysis
16.11.3.1 Revenue, 2018-2022
16.11.3.2 Regional Market Shares, 2022
16.11.4 Product Benchmarking
16.12 Amneal Pharmaceuticals LLC
16.12.1 Company Snapshot
16.12.2 Company Overview
16.12.3 Financial Analysis
16.12.3.1 Revenue, 2018-2022
16.12.3.2 R&D Expense, 2018-2022
16.12.4 Product Benchmarking
16.12.5 Strategic Outlook
16.13 Dr. Reddy’s Laboratories Ltd.
16.13.1 Company Snapshot
16.13.2 Company Overview
16.13.3 Financial Analysis
16.13.3.1 Revenue, 2018-2022
16.13.3.2 Regional Market Shares, 2022
16.13.3.3 R&D Expense, 2018-2022
16.13.4 Product Benchmarking
16.13.5 Strategic Outlook
16.14 Sun Pharmaceutical Industries Ltd.
16.14.1 Company Snapshot
16.14.2 Company Overview
16.14.3 Financial Analysis
16.14.3.1 Revenue, 2018-2022
16.14.3.2 R&D Expense, 2018-2022
16.14.4 Product Benchmarking
16.14.5 Strategic Outlook
17 Conclusion and Recommendations
17.1 Concluding Remarks from Visiongain
17.2 Recommendations for Market Players
List of Tables
Table 1 Generic Drugs Market Snapshot, 2024 & 2034 (US$ billion, CAGR %)
Table 2 Patent Expiration
Table 3 Global Generic Drugs Market Forecast by Region 2024-2034 (US$ Billion, AGR%, CAGR%): "V" Shaped Recovery
Table 4 Generic Drugs Market Forecast by Region 2024-2034 (US$ Billion, AGR%, CAGR%): "U" Shaped Recovery
Table 5 Global Generic Drugs Market Forecast by Region 2024-2034 (US$ Billion, AGR%, CAGR%): "W" Shaped Recovery
Table 6 Global Generic Drugs Market Forecast by Region 2024-2034 (US$ Billion, AGR%, CAGR%): "L" Shaped Recovery
Table 7 Generic Drugs Market Forecast by Type, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 8 Simple Generics Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 9 Specialty Generics Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 10 Biosimilars Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 11 Generic Drugs Market Forecast by Type, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 12 Prescription Generics Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 13 Over-the-Counter (OTC) Generics Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 14 Generic Drugs Market Forecast by Indication, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 15 Central Nervous System (CNS) Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 16 Oncology Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 17 Infectious Diseases Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 18 Cardiovascular Diseases Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 19 Gastrointestinal Diseases Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 20 Musculoskeletal Diseases Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 21 Others Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 22 Generic Drugs Market Forecast by Drug Class, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 23 Antibiotics Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 24 Antihistamines Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 25 Analgesics Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 26 Antihypertensive Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 27 Antidiabetic Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 28 Antipyretic Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 29 Others Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 30 Generic Drugs Market Forecast by Route of Administration, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 31 Oral Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 32 Parenteral Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 33 Topical Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 34 Others Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 35 Generic Drugs Market Forecast by Distribution Channel, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 36 Hospital Pharmacies Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 37 Retail Pharmacies Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 38 Online Pharmacies Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 39 Others Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 40 Global Generic drugs Market Forecast by Region 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 41 North America Generic Drugs Market Forecast by Country, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 42 North America Generic Drugs Market Forecast by Type, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 43 North America Generic Drugs Market Forecast by Route of Administration, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 44 North America Generic Drugs Market Forecast by Indication, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 45 North America Generic Drugs Market Forecast by Drug Class, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 46 North America Generic drugs Market Forecast by Prescription Type, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 47 North America Generic Drugs Market Forecast by Distribution Channel, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 48 U.S. Generic Drugs Market Forecast by Country, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 49 Canada Generic Drugs Market Forecast by Country, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 50 Europe Generic Drugs Market Forecast by Country, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 51 Europe Generic Drugs Market Forecast by Type, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 52 Europe Generic Drugs Market Forecast by Route of Administration, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 53 Europe Generic Drugs Market Forecast by Indication, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 54 Europe Generic Drugs Market Forecast by Drug Class, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 55 Europe Generic drugs Market Forecast by Prescription Type, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 56 Europe Generic Drugs Market Forecast by Distribution Channel, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 57 Germany Generic Drugs Market Forecast by Country, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 58 UK Generic Drugs Market Forecast, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 59 France Generic Drugs Market Forecast, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 60 Italy Generic Drugs Market Forecast, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 61 Spain Generic Drugs Market Forecast, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 62 Rest of Europe Generic Drugs Market Forecast, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 63 Asia Pacific Generic Drugs Market Forecast by Country, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 64 Asia Pacific Generic Drugs Market Forecast by Type, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 65 Asia Pacific Generic Drugs Market Forecast by Route of Administration, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 66 Asia Pacific Generic Drugs Market Forecast by Indication, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 67 Asia Pacific Generic Drugs Market Forecast by Drug Class, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 68 Asia Pacific Generic drugs Market Forecast by Prescription Type, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 69 Asia Pacific Generic Drugs Market Forecast by Distribution Channel, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 70 Japan Generic Drugs Market Forecast, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 71 China Generic Drugs Market Forecast, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 72 India Generic Drugs Market Forecast, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 73 Australia Generic Drugs Market Forecast, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 74 South Korea Generic Drugs Market Forecast, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 75 Rest of Asia-Pacific Generic Drugs Market Forecast, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 76 Latin America Generic Drugs Market Forecast by Country, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 77 Latin America Generic Drugs Market Forecast by Type, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 78 Latin America Generic Drugs Market Forecast by Route of Administration, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 79 Latin America Generic Drugs Market Forecast by Indication, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 80 Latin America Generic Drugs Market Forecast by Drug Class, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 81 Latin America Generic drugs Market Forecast by Prescription Type, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 82 Latin America Generic Drugs Market Forecast by Distribution Channel, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 83 Brazil Generic Drugs Market Forecast, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 84 Argentina Generic Drugs Market Forecast, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 85 Rest of Latin America Generic Drugs Market Forecast, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 86 MEA Generic Drugs Market Forecast by Country, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 87 MEA Generic Drugs Market Forecast by Type, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 88 MEA Generic Drugs Market Forecast by Route of Administration, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 89 MEA Generic Drugs Market Forecast by Indication, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 90 MEA Generic Drugs Market Forecast by Drug Class, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 91 MEA Generic drugs Market Forecast by Prescription Type, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 92 MEA Generic Drugs Market Forecast by Distribution Channel, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 93 GCC Generic Drugs Market Forecast, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 94 South Africa Generic Drugs Market Forecast, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 95 Rest of MEA Generic Drugs Market Forecast, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 96 Novartis AG: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 97 Novartis AG: Product Benchmarking
Table 98 Novartis AG: Strategic Outlook
Table 99 Teva Pharmaceutical Industries Ltd.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 100 Teva Pharmaceutical Industries Ltd.: Product Benchmarking
Table 101 Teva Pharmaceutical Industries Ltd.: Strategic Outlook
Table 102 Viatris Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 103 Viatris Inc.: Product Benchmarking
Table 104 Viatris Inc.: Strategic Outlook
Table 105 Lupin: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 106 Lupin: Product Benchmarking
Table 107 Lupin: Strategic Outlook
Table 108 Alkem Laboratories Ltd.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 109 Alkem Laboratories Ltd.: Product Benchmarking
Table 110 Alkem Laboratories Ltd.: Strategic Outlook
Table 111 Cipla Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 112 Cipla Inc.: Product Benchmarking
Table 113 Cipla Inc.: Strategic Outlook
Table 114 Biocon: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 115 Biocon: Product Benchmarking
Table 116 Biocon: Strategic Outlook
Table 117 Aurobindo Pharma: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 118 Aurobindo Pharma: Product Benchmarking
Table 119 Aurobindo Pharma: Strategic Outlook
Table 120 Endo International plc: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 121 Endo International plc: Product Benchmarking
Table 122 Endo International plc: Strategic Outlook
Table 123 Torrent Pharmaceuticals Ltd.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 124 Torrent Pharmaceuticals Ltd.: Product Benchmarking
Table 125 Amneal Pharmaceuticals LLC: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 126 Amneal Pharmaceuticals LLC: Product Benchmarking
Table 127 Amneal Pharmaceuticals LLC: Strategic Outlook
Table 128 Dr. Reddy’s Laboratories Ltd.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 129 Dr. Reddy’s Laboratories Ltd.: Product Benchmarking
Table 130 Dr. Reddy’s Laboratories Ltd.: Strategic Outlook
Table 131 Sun Pharmaceutical Industries Ltd.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 132 Sun Pharmaceutical Industries Ltd.: Product Benchmarking
Table 133 Sun Pharmaceutical Industries Ltd.: Strategic Outlook
List of Figures
Figure 1 Generic Drugs Market Segmentation
Figure 2 Generic Drugs Market by Type: Market Attractiveness Index
Figure 3 Generic Drugs Market Forecast by Route of Administration: Market Attractiveness Index
Figure 4 Generic Drugs Market Forecast by Indication: Market Attractiveness Index
Figure 5 Generic Drugs Market Forecast by Indication: Market Attractiveness Index
Figure 6 Generic Drugs Market Forecast by Prescription Type: Market Attractiveness Index
Figure 7 Generic Drugs Market Forecast by Distribution Channel: Market Attractiveness Index
Figure 8 Generic Drugs Market Attractiveness Index by Region
Figure 9 Global Generic Drugs Market: Market Dynamics
Figure 10 Generic Drugs Market by Region, 2024-2034 (US$ Billion, AGR (%), CAGR (%)): “V” Shaped Recovery
Figure 11 Generic Drugs Market by Region, 2024-2034 (US$ Billion, AGR (%), CAGR (%)): “U” Shaped Recovery
Figure 12 Generic Drugs Market by Region, 2024-2034 (US$ Billion, AGR (%), CAGR (%)): “W” Shaped Recovery
Figure 13 Generic Drugs Market by Region, 2024-2034 (US$ Billion, AGR (%), CAGR (%)): “L” Shaped Recovery
Figure 14 Generic drugs Market: Porter’s Five Forces Analysis
Figure 15 Generic Drugs Market: PEST Analysis
Figure 16 Generic Drugs Market Forecast by Type: Market Attractiveness Index
Figure 17 Generic Drugs Market Forecast by Type, 2024-2034 (US$ Billion)
Figure 18 Generic Drugs Market Share Forecast by Type, 2024, 2029, 2034 (%)
Figure 19 Simple Generics Market Forecast by Region, 2024-2034 (US$ Billion, AGR %)
Figure 20 Simple Generics Market Share Forecast by Region, 2024 & 2034 (%)
Figure 21 Specialty Generics Market Forecast by Region, 2024-2034 (US$ Billion, AGR %)
Figure 22 Specialty Generics Market Share Forecast by Region, 2024 & 2034 (%)
Figure 23 Biosimilars Market Forecast by Region, 2024-2034 (US$ Billion, AGR %)
Figure 24 Biosimilars Market Share Forecast by Region, 2024 & 2034 (%)
Figure 25 Generic Drugs Market Forecast by Prescription Type: Market Attractiveness Index
Figure 26 Generic Drugs Market Forecast By Prescription Type, 2024-2034 (US$ Billion, AGR %)
Figure 27 Generic Drugs Market Share Forecast by Prescription Type, 2024, 2029, 2034 (%)
Figure 28 Prescription Generics Market Forecast by Region, 2024-2034 (US$ Billion, AGR %)
Figure 29 Prescription Generics Market Share Forecast by Region, 2024 & 2034 (%)
Figure 30 Over-the-Counter (OTC) Generics Market Forecast by Region, 2024-2034 (US$ Billion, AGR %)
Figure 31 Over-the-Counter (OTC) Generics Market Share Forecast by Region, 2024 & 2034 (%)
Figure 32 Generic Drugs Market Forecast by Indication: Market Attractiveness Index
Figure 33 Generic Drugs Market Forecast By Indication, 2024-2034 (US$ Billion, AGR %)
Figure 34 Generic Drugs Market Share Forecast by Indication, 2024, 2029, 2034 (%)
Figure 35 Central Nervous System (CNS) Market Forecast by Region, 2024-2034 (US$ Billion, AGR %)
Figure 36 Central Nervous System (CNS) Market Share Forecast by Region, 2024 & 2034 (%)
Figure 37 Oncology Market Forecast by Region, 2024-2034 (US$ Billion, AGR %)
Figure 38 Oncology Market Share Forecast by Region, 2024 & 2034 (%)
Figure 39 Infectious Diseases Market Forecast by Region, 2024-2034 (US$ Billion, AGR %)
Figure 40 Infectious Diseases Market Share Forecast by Region, 2024 & 2034 (%)
Figure 41 Cardiovascular Diseases Market Forecast by Region, 2024-2034 (US$ Billion, AGR %)
Figure 42 Cardiovascular Diseases Market Share Forecast by Region, 2024 & 2034 (%)
Figure 43 Gastrointestinal Diseases Market Forecast by Region, 2024-2034 (US$ Billion, AGR %)
Figure 44 Gastrointestinal Diseases Market Share Forecast by Region, 2024 & 2034 (%)
Figure 45 Musculoskeletal Diseases Market Forecast by Region, 2024-2034 (US$ Billion, AGR %)
Figure 46 Musculoskeletal Diseases Market Share Forecast by Region, 2024 & 2034 (%)
Figure 47 Others Market Forecast by Region, 2024-2034 (US$ Billion, AGR %)
Figure 48 Others Market Share Forecast by Region, 2024 & 2034 (%)
Figure 49 Generic Drugs Market Forecast by Drug Class: Market Attractiveness Index
Figure 50 Generic Drugs Market Forecast By Drug Class, 2024-2034 (US$ Billion, AGR %)
Figure 51 Generic Drugs Market Share Forecast by Drug Class, 2024, 2029, 2034 (%)
Figure 52 Antibiotics Market Forecast by Region, 2024-2034 (US$ Billion, AGR %)
Figure 53 Antibiotics Market Share Forecast by Region, 2024 & 2034 (%)
Figure 54 Antihistamines Market Forecast by Region, 2024-2034 (US$ Billion, AGR %)
Figure 55 Antihistamines Market Share Forecast by Region, 2024 & 2034 (%)
Figure 56 Analgesics Market Forecast by Region, 2024-2034 (US$ Billion, AGR %)
Figure 57 Analgesics Market Share Forecast by Region, 2024 & 2034 (%)
Figure 58 Antihypertensive Market Forecast by Region, 2024-2034 (US$ Billion, AGR %)
Figure 59 Antihypertensive Market Share Forecast by Region, 2024 & 2034 (%)
Figure 60 Antidiabetic Market Forecast by Region, 2024-2034 (US$ Billion, AGR %)
Figure 61 Antidiabetic Market Share Forecast by Region, 2024 & 2034 (%)
Figure 62 Antipyretic Market Forecast by Region, 2024-2034 (US$ Billion, AGR %)
Figure 63 Antipyretic Market Share Forecast by Region, 2024 & 2034 (%)
Figure 64 Others Market Forecast by Region, 2024-2034 (US$ Billion, AGR %)
Figure 65 Others Market Share Forecast by Region, 2024 & 2034 (%)
Figure 66 Generic Drugs Market Forecast by Route of Administration: Market Attractiveness Index
Figure 67 Generic Drugs Market Forecast By Route of Administration, 2024-2034 (US$ Billion, AGR %)
Figure 68 Generic Drugs Market Share Forecast by Route of Administration, 2024, 2029, 2034 (%)
Figure 69 Oral Market Forecast by Region, 2024-2034 (US$ Billion, AGR %)
Figure 70 Oral Market Share Forecast by Region, 2024 & 2034 (%)
Figure 71 Parenteral Market Forecast by Region, 2024-2034 (US$ Billion, AGR %)
Figure 72 Parenteral Market Share Forecast by Region, 2024 & 2034 (%)
Figure 73 Topical Market Forecast by Region, 2024-2034 (US$ Billion, AGR %)
Figure 74 Topical Market Share Forecast by Region, 2024 & 2034 (%)
Figure 75 Others Market Forecast by Region, 2024-2034 (US$ Billion, AGR %)
Figure 76 Others Market Share Forecast by Region, 2024 & 2034 (%)
Figure 77 Generic Drugs Market Forecast by Distribution Channel: Market Attractiveness Index
Figure 78 Generic Drugs Market Forecast By Distribution Channel, 2024-2034 (US$ Billion, AGR %)
Figure 79 Generic Drugs Market Share Forecast by Distribution Channel, 2024, 2029, 2034 (%)
Figure 80 Hospital Pharmacies Market Forecast by Region, 2024-2034 (US$ Billion, AGR %)
Figure 81 Hospital Pharmacies Market Share Forecast by Region, 2024 & 2034 (%)
Figure 82 Retail Pharmacies Market Forecast by Region, 2024-2034 (US$ Billion, AGR %)
Figure 83 Retail Pharmacies Market Share Forecast by Region, 2024 & 2034 (%)
Figure 84 Online Pharmacies Market Forecast by Region, 2024-2034 (US$ Billion, AGR %)
Figure 85 Online Pharmacies Market Share Forecast by Region, 2024 & 2034 (%)
Figure 86 Others Market Forecast by Region, 2024-2034 (US$ Billion, AGR %)
Figure 87 Others Market Share Forecast by Region, 2024 & 2034 (%)
Figure 88 Generic Drugs Market Forecast by Region, 2024 & 2034 (Revenue, CAGR%)
Figure 89 Generic Drugs Market Share Forecast by Region 2024, 2029, 2034(%)
Figure 90 Generic Drugs Market by Region, 2024-2034 (US$ Billion, AGR (%), CAGR (%))
Figure 91 North America Generic Drugs Market Attractiveness Index
Figure 92 North America Generic Drugs Market by Region, 2024, 2029 & 2034 (US$ Billion)
Figure 93 North America Generic Drugs Market Forecast by Country, 2024-2034 (US$ Billion, AGR %)
Figure 94 North America Generic Drugs Market Share Forecast by Country, 2024 & 2034 (%)
Figure 95 North America Generic Drugs Market Forecast by Type, 2024-2034 (US$ Billion, AGR %)
Figure 96 North America Generic Drugs Market Share Forecast by Type, 2024 & 2034 (%)
Figure 97 North America Generic Drugs Market Forecast by Route of Administration, 2024-2034 (US$ Billion, AGR %)
Figure 98 North America Generic Drugs Market Share Forecast by Route of Administration, 2024 & 2034 (%)
Figure 99 North America Generic Drugs Market Forecast by Indication, 2024-2034 (US$ Billion, AGR %)
Figure 100 North America Generic Drugs Market Share Forecast by Indication, 2024 & 2034 (%)
Figure 101 North America Generic Drugs Market Forecast by Drug Class, 2024-2034 (US$ Billion, AGR %)
Figure 102 North America Generic Drugs Market Share Forecast by Drug Class, 2024 & 2034 (%)
Figure 103 North America Generic Drugs Market Forecast by Prescription Type, 2024-2034 (US$ Billion, AGR %)
Figure 104 North America Generic Drugs Market Share Forecast by Prescription Type, 2024 & 2034 (%)
Figure 105 North America Generic Drugs Market Forecast by Distribution Channel, 2024-2034 (US$ Billion, AGR %)
Figure 106 North America Generic Drugs Market Share Forecast by Distribution Channel, 2024 & 2034 (%)
Figure 107 U.S. Generic Drugs Market Forecast, 2024-2034 (US$ Billion, AGR %)
Figure 108 Canada Generic Drugs Market Forecast, 2024-2034 (US$ Billion, AGR %)
Figure 109 Europe Generic Drugs Market Attractiveness Index
Figure 110 Europe Generic Drugs Market by Region, 2024, 2029 & 2034 (US$ Billion)
Figure 111 Europe Generic Drugs Market Forecast by Country, 2024-2034 (US$ Billion, AGR %)
Figure 112 Europe Generic Drugs Market Share Forecast by Country, 2024 & 2034 (%)
Figure 113 Europe Generic Drugs Market Forecast by Type, 2024-2034 (US$ Billion, AGR %)
Figure 114 Europe Generic Drugs Market Share Forecast by Type, 2024 & 2034 (%)
Figure 115 Europe Generic Drugs Market Forecast by Route of Administration, 2024-2034 (US$ Billion, AGR %)
Figure 116 Europe Generic Drugs Market Share Forecast by Route of Administration, 2024 & 2034 (%)
Figure 117 Europe Generic Drugs Market Forecast by Indication, 2024-2034 (US$ Billion, AGR %)
Figure 118 Europe Generic Drugs Market Share Forecast by Indication, 2024 & 2034 (%)
Figure 119 Europe Generic Drugs Market Forecast by Drug Class, 2024-2034 (US$ Billion, AGR %)
Figure 120 Europe Generic Drugs Market Share Forecast by Drug Class, 2024 & 2034 (%)
Figure 121 Europe Generic Drugs Market Forecast by Prescription Type, 2024-2034 (US$ Billion, AGR %)
Figure 122 Europe Generic Drugs Market Share Forecast by Prescription Type, 2024 & 2034 (%)
Figure 123 Europe Generic Drugs Market Forecast by Distribution Channel, 2024-2034 (US$ Billion, AGR %)
Figure 124 Europe Generic Drugs Market Share Forecast by Distribution Channel, 2024 & 2034 (%)
Figure 125 Germany Generic Drugs Market Forecast, 2024-2034 (US$ Billion, AGR %)
Figure 126 U.K. Generic Drugs Market Forecast, 2024-2034 (US$ Billion, AGR %)
Figure 127 France Generic Drugs Market Forecast, 2024-2034 (US$ Billion, AGR %)
Figure 128 Italy Generic Drugs Market Forecast, 2024-2034 (US$ Billion, AGR %)
Figure 129 Spain Generic Drugs Market Forecast, 2024-2034 (US$ Billion, AGR %)
Figure 130 Rest of Europe Generic Drugs Market Forecast, 2024-2034 (US$ Billion, AGR %)
Figure 131 Asia Pacific Generic Drugs Market Attractiveness Index
Figure 132 Asia Pacific Generic Drugs Market by Region, 2024, 2029 & 2034 (US$ Billion)
Figure 133 Asia Pacific Generic Drugs Market Forecast by Country, 2024-2034 (US$ Billion, AGR %)
Figure 134 Asia Pacific Generic Drugs Market Share Forecast by Country, 2024 & 2034 (%)
Figure 135 Asia Pacific Generic Drugs Market Forecast by Type, 2024-2034 (US$ Billion, AGR %)
Figure 136 Asia Pacific Generic Drugs Market Share Forecast by Type, 2024 & 2034 (%)
Figure 137 Asia Pacific Generic Drugs Market Forecast by Route of Administration, 2024-2034 (US$ Billion, AGR %)
Figure 138 Asia Pacific Generic Drugs Market Share Forecast by Route of Administration, 2024 & 2034 (%)
Figure 139 Asia Pacific Generic Drugs Market Forecast by Indication, 2024-2034 (US$ Billion, AGR %)
Figure 140 Asia Pacific Generic Drugs Market Share Forecast by Indication, 2024 & 2034 (%)
Figure 141 Asia Pacific Generic Drugs Market Forecast by Drug Class, 2024-2034 (US$ Billion, AGR %)
Figure 142 Asia Pacific Generic Drugs Market Share Forecast by Drug Class, 2024 & 2034 (%)
Figure 143 Asia Pacific Generic Drugs Market Forecast by Prescription Type, 2024-2034 (US$ Billion, AGR %)
Figure 144 Asia Pacific Generic Drugs Market Share Forecast by Prescription Type, 2024 & 2034 (%)
Figure 145 Asia Pacific Generic Drugs Market Forecast by Distribution Channel, 2024-2034 (US$ Billion, AGR %)
Figure 146 Asia Pacific Generic Drugs Market Share Forecast by Distribution Channel, 2024 & 2034 (%)
Figure 147 Japan Generic Drugs Market Forecast, 2024-2034 (US$ Billion, AGR %)
Figure 148 China Generic Drugs Market Forecast, 2024-2034 (US$ Billion, AGR %)
Figure 149 India Generic Drugs Market Forecast, 2024-2034 (US$ Billion, AGR %)
Figure 150 Australia Generic Drugs Market Forecast, 2024-2034 (US$ Billion, AGR %)
Figure 151 South Korea Generic Drugs Market Forecast, 2024-2034 (US$ Billion, AGR %)
Figure 152 Rest of Asia Pacific Generic Drugs Market Forecast, 2024-2034 (US$ Billion, AGR %)
Figure 153 Latin America Generic Drugs Market Attractiveness Index
Figure 154 Latin America Generic Drugs Market by Region, 2024, 2029 & 2034 (US$ Billion)
Figure 155 Latin America Generic Drugs Market Forecast by Country, 2024-2034 (US$ Billion, AGR %)
Figure 156 Latin America Generic Drugs Market Share Forecast by Country, 2024 & 2034 (%)
Figure 157 Latin America Generic Drugs Market Forecast by Type, 2024-2034 (US$ Billion, AGR %)
Figure 158 Latin America Generic Drugs Market Share Forecast by Type, 2024 & 2034 (%)
Figure 159 Latin America Generic Drugs Market Forecast by Route of Administration, 2024-2034 (US$ Billion, AGR %)
Figure 160 Latin America Generic Drugs Market Share Forecast by Route of Administration, 2024 & 2034 (%)
Figure 161 Latin America Generic Drugs Market Forecast by Indication, 2024-2034 (US$ Billion, AGR %)
Figure 162 Latin America Generic Drugs Market Share Forecast by Indication, 2024 & 2034 (%)
Figure 163 Latin America Generic Drugs Market Forecast by Drug Class, 2024-2034 (US$ Billion, AGR %)
Figure 164 Latin America Generic Drugs Market Share Forecast by Drug Class, 2024 & 2034 (%)
Figure 165 Latin America Generic Drugs Market Forecast by Prescription Type, 2024-2034 (US$ Billion, AGR %)
Figure 166 Latin America Generic Drugs Market Share Forecast by Prescription Type, 2024 & 2034 (%)
Figure 167 Latin America Generic Drugs Market Forecast by Distribution Channel, 2024-2034 (US$ Billion, AGR %)
Figure 168 Latin America Generic Drugs Market Share Forecast by Distribution Channel, 2024 & 2034 (%)
Figure 169 Brazil Generic Drugs Market Forecast, 2024-2034 (US$ Billion, AGR %)
Figure 170 Argentina Generic Drugs Market Forecast, 2024-2034 (US$ Billion, AGR %)
Figure 171 Rest of Latin America Generic Drugs Market Forecast, 2024-2034 (US$ Billion, AGR %)
Figure 172 MEA Generic Drugs Market Attractiveness Index
Figure 173 MEA Generic Drugs Market by Region, 2024, 2029 & 2034 (US$ Billion)
Figure 174 MEA Generic Drugs Market Forecast by Country, 2024-2034 (US$ Billion, AGR %)
Figure 175 MEA Generic Drugs Market Share Forecast by Country, 2024 & 2034 (%)
Figure 176 MEA Generic Drugs Market Forecast by Type, 2024-2034 (US$ Billion, AGR %)
Figure 177 MEA Generic Drugs Market Share Forecast by Type, 2024 & 2034 (%)
Figure 178 MEA Generic Drugs Market Forecast by Route of Administration, 2024-2034 (US$ Billion, AGR %)
Figure 179 MEA Generic Drugs Market Share Forecast by Route of Administration, 2024 & 2034 (%)
Figure 180 MEA Generic Drugs Market Forecast by Indication, 2024-2034 (US$ Billion, AGR %)
Figure 181 MEA Generic Drugs Market Share Forecast by Indication, 2024 & 2034 (%)
Figure 182 MEA Generic Drugs Market Forecast by Drug Class, 2024-2034 (US$ Billion, AGR %)
Figure 183 MEA Generic Drugs Market Share Forecast by Drug Class, 2024 & 2034 (%)
Figure 184 MEA Generic Drugs Market Forecast by Prescription Type, 2024-2034 (US$ Billion, AGR %)
Figure 185 MEA Generic Drugs Market Share Forecast by Prescription Type, 2024 & 2034 (%)
Figure 186 MEA Generic Drugs Market Forecast by Distribution Channel, 2024-2034 (US$ Billion, AGR %)
Figure 187 MEA Generic Drugs Market Share Forecast by Distribution Channel, 2024 & 2034 (%)
Figure 188 GCC Generic Drugs Market Forecast, 2024-2034 (US$ Billion, AGR %)
Figure 189 South Africa Generic Drugs Market Forecast, 2024-2034 (US$ Billion, AGR %)
Figure 190 Rest of MEA Generic Drugs Market Forecast, 2024-2034 (US$ Billion, AGR %)
Figure 191 Generic Drugs Market: Company Share Analysis, 2023
Figure 192 Novartis AG: Net Revenue, 2018-2022 (US$ Million, AGR%)
Figure 193 Novartis AG: Regional Market Shares, 2022
Figure 194 Novartis AG: R&D Expense, 2018-2022 (US$ Million, AGR%)
Figure 195 Teva Pharmaceutical Industries Ltd.: Annual Revenue, 2018-2022 (US$ million, AGR%)
Figure 196 Teva Pharmaceutical Industries Ltd: Regional Market Shares, 2022
Figure 197 Teva Pharmaceutical Industries Ltd.: R&D Expense, 2018-2022 (US$ Million, AGR%)
Figure 198 Viatris Inc.: Annual Revenue, 2018-2022 (US$ Million, AGR%)
Figure 199 Viatris Inc.: Regional Market Shares, 2022
Figure 200 Viatris Inc.: R&D Expense, 2018-2022 (US$ Million, AGR%)
Figure 201 Lupin: Net Revenue, 2018-2022 (US$ Million, AGR%)
Figure 202 Lupin: R&D Expense, 2018-2022 (US$ Million, AGR%)
Figure 203 Alkem Laboratories Ltd.: Net Revenue, 2018-2022 (US$ Million, AGR%)
Figure 204 Alkem Laboratories Ltd.: Regional Market Shares, 2022
Figure 205 Alkem Laboratories Ltd.: R&D Expense, 2018-2022 (US$ Million, AGR%)
Figure 206 Cipla Inc.: Net Revenue, 2018-2022 (US$ Million, AGR%)
Figure 207 Cipla Inc.: Regional Market Shares, 2022
Figure 208 Cipla Inc.: R&D Expense, 2018-2022 (US$ Million, AGR%)
Figure 209 Biocon: Net Revenue, 2018-2022 (US$ Million, AGR%)
Figure 210 Biocon: Segmental Market Shares, 2022
Figure 211 Biocon: R&D Expense, 2018-2022 (US$ Million, AGR%)
Figure 212 Aurobindo Pharma: Net Revenue, 2018-2022 (US$ Million, AGR%)
Figure 213 Endo International plc: Net Revenue, 2018-2022 (US$ Million, AGR%)
Figure 214 Endo International plc..: R&D Expense, 2018-2022 (US$ Million, AGR%)
Figure 215 Torrent Pharmaceuticals Ltd.: Net Revenue, 2018-2022 (US$ Million, AGR%)
Figure 216 Torrent Pharmaceuticals Ltd.: Regional Market Shares, 2022
Figure 217 Amneal Pharmaceuticals LLC: Net Revenue, 2018-2022 (US$ Million, AGR%)
Figure 218 Amneal Pharmaceuticals LLC: R&D Expense, 2018-2022 (US$ Million, AGR%)
Figure 219 Dr. Reddy’s Laboratories Ltd.: Net Revenue, 2018-2022 (US$ Million, AGR%)
Figure 220 Dr. Reddy’s Laboratories Ltd.: Regional Market Shares, 2022
Figure 221 Dr. Reddy’s Laboratories Ltd.: R&D Expense, 2018-2022 (US$ Million, AGR%)
Figure 222 Sun Pharmaceutical Industries Ltd.: Net Revenue, 2018-2022 (US$ Million, AGR%)
Figure 223 Sun Pharmaceutical Industries Ltd.: R&D Expense, 2018-2022 (US$ Million, AGR%)
List of Companies Profiled in the report
Alkem Laboratories Ltd.
Amneal Pharmaceuticals LLC
Aurobindo Pharma
Biocon
Cipla Inc.
Dr. Reddy's Laboratories Ltd.
Endo International plc
Lupin
Novartis AG
Sun Pharmaceuticals Industries Ltd.
Teva Pharmaceutical Industries Ltd.
Torrent Pharmaceuticals Ltd.
Viatris Inc.
List of Other Companies Mentioned in the report
AbbVie
Aché Farmaceutica
Alvion
Bayer
Celgene
Celltrion
Coherus BioSciences
Eli Lily
GSK
Hetero Labs
Hexal
Hikma Pharmaceuticals
Huahai Pharmaceutical
Laboratorio Elea Phoenix
Merck
Pfizer
Piyavate Pharma
Procter & Hamble
Roche
Strides Pharma
Zydus Cadila
List of Associations Mentioned in the Report
Central Drugs Standard Control Organization (CDSCO)
China Food and Drug Administration (CFDA)
European Medicines Agency (EMA)
Federal Institute for Drugs and Medical Devices
Italian Medicines Agency (AIFA)
Ministry of Food and Drug Safety (MFDS)
Ministry of Health (MOH)
Ministry of Health, Labour and Welfare (MHLW)
National Medical Products Administration (NMPA)
Pharmaceuticals and Medical Devices Agency (PMDA)
Therapeutic Goods Administration (TGA)
U.S. Food and Drug Administration (FDA)
World Health Organization (WHO)
Visiongain Pharma
Visiongain Pharma
Visiongain Pharma
